Blocking the IL-4/IL-13 pathway shows efficacy for treating the inflammatory aspects of many, but not all, patients with moderate-to-severe AD, stressing the need for precision medicine with stratification by comorbidities and other phenotypic traits as well as the endotype [3,130]. Here, IL13 is linked to Alzheimer disease.